Navigation Links
HERmark(TM) Assay Results in Metastatic Breast Cancer Presented at the San Antonio Breast Cancer Symposium
Date:12/14/2007

HER2 Homodimer and HER2 Total Protein Assays Validated in CLIA Laboratory

SOUTH SAN FRANCISCO, Dec. 14 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today presented the results of a study detailing the HERmark(TM) Assay's ability to identify metastatic breast cancer patients who are most likely to respond to Herceptin(R). The study results were presented this week at the San Antonio Breast Cancer Symposium. Also this week, Monogram received confirmation from the College of Pathologists (CAP) that the HERmark assays are approved for routine patient testing in Monogram's CLIA certified clinical reference laboratory.

"The results presented today are an important step along the way to clinical validation of HERmark, the first product based on the VeraTag technology platform," said William Young, Monogram chief executive officer. "In addition to the presentation of important clinical data, I am pleased to report today that the HERmark assays have completed their validation process in Monogram's CLIA-certified clinical reference laboratory. The establishment of solid technical validation data and the ability to perform the assays under high-throughput, well controlled conditions will provide a strong basis for commercialization of HERmark after completion of our ongoing clinical studies."

In the study reported today, Monogram analyzed tissue samples from patients with metastatic breast cancer who were treated with Herceptin, having been selected for such treatment by centralized IHC testing. While current testing methods identified all these patients as being appropriate for Herceptin treatment, Monogram's HERmark Assay was able to distinguish separate sub-populations of patients with different clinical o
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
4. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Tapestry Reports Second Quarter 2007 Results
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
(Date:12/16/2009)... Dec. 16 Naurex Inc., a new ... and other CNS disorders based on its novel ... presented at a major medical meeting showed that ... anxiolytic-like activity with no signs of the CNS-related ... NMDA receptor(1). The studies also showed that ...
(Date:12/16/2009)... NEW YORK, Dec. 16 Keryx ... today the initiation of a Phase 3 ... Company,s PI3K/Akt pathway inhibitor, in relapsed / ... entitled, "A Phase 3 Randomized Study to ... Added to the Combination of Bortezomib (Velcade®) ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 1New Directions in Angioedema 3A A Focus on Etiologies and Clinical Approach 48496 2Parents key in new measure to evaluate language in children with autism 48494 1Parents key in new measure to evaluate language in children with autism 48494 2Parents key in new measure to evaluate language in children with autism 48494 3Pre pregnancy depressed mood may heighten risk for premature birth 8792 1Pre pregnancy depressed mood may heighten risk for premature birth 8792 2Pre pregnancy depressed mood may heighten risk for premature birth 8792 3
... ARIAD,Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical,investigators ... and,1b clinical data from ongoing trials of the ... of the American Society,of Clinical Oncology (ASCO) in ... from the Phase 2 trial of single-agent,AP23573 in ...
... /PRNewswire-FirstCall/ -- Iomai,Corporation today announced that it will ... patch-based needle-free influenza vaccine,before the markets open tomorrow. ... at 8:30 a.m. Eastern Time tomorrow to discuss,the ... the live conference call Friday, May 25, 2007 ...
Other Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:12/16/2009)... Quantros, Inc., a leading provider of safety and ... healthcare industry, announces the creation of a new ... industry veteran Michael Tulloch, MBA, as Director of ... company,s new Marlborough, MA office. ,, "The expansion ... Tulloch. "Quantros has been developing software for the ...
(Date:12/16/2009)... What happens when the families of sick and dying ... or for them? How do pediatricians respond to such ... religion and spirituality help some patients and families cope ... is almost always the families and patients who raise ... In the current issue of Southern Medical Journal ...
(Date:12/16/2009)... Dec. 16 Tyco International Ltd. (NYSE: ... of Michael E. Daniels for election to the ... General Meeting on March 10, 2010. ,, ... Global Technology Services group of International Business Machines ... for IBM,s Global Services business operations consisting of ...
(Date:12/16/2009)... While many of the,pharma companies are struggling ... and inmarket drugs, MarketsandMarkets on the other ... players. These pharma,forecasting solutions are designed for ... phase,III. These have a substantial impact on ... strategy, manufacturing planning, sales force,promotion, and planning. ...
(Date:12/16/2009)... donates time and money to help clothe children in need. ... ... Florida dry cleaner Dryclean USA Florida , along with Atlantic ... Hope to help clothe children in need by collecting funds ... will begin distributing cards, with delivery of their clean clothes, and ...
Breaking Medicine News(10 mins):Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pay a Dollar, Dress a Child: Helping Struggling Families with Small Donations 2
... Internet - , , ANTHEM, Ariz., Dec. 29 ... of its new web site at http://www.mychoicedentist.com and ... Phoenix , Arizona, area is proceeding successfully. "Arizona is ... CEO. "We anticipate expanding this service to almost every major ...
... Now Worth Twenty-Five Thousand Dollars at www.MaxMuscle.com/max-formation/ , ... ... Sports Nutrition is rewarding $25,000 cash to the individual who can ... lean muscle and fitness in 2009., , , , ,Bring Yourself ...
... Critically ill patients frequently have uncertain prognoses, but ... prognostic uncertainty candidly, according to a new study ... Center. , "Our interviews revealed that caregivers ... and just the nature of life," said lead ...
... a timely reminder of the issues surrounding the binge ... people and alcohol, a team lead by Professor Christine ... funded by the Economic and Social Research Council (ESRC) ... Focusing on the role of marketing practices in shaping ...
... Team Sponsored by Land Rover, St. Regis Resort Aspen, National ... Land Rover America,s Polo Cup Team participated in the prestigious ... weekend filled with world class polo and camaraderie on and ... was comprised of John Gobin at 8 goals, (one of ...
... against troublesome complication, study finds , , FRIDAY, Dec. 26 ... before cardiac surgery may lower their chances of having ... on variables such as age and the complexity of ... this condition of confusion following heart surgery. The condition ...
Other Medicine News:Health News:Prime Companies Announces Launch of New Dental Web Site 2Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 2Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 3Health News:Max Muscle Sports Nutrition Offers $25,000 Reward For Your New Years Resolution 4Health News:Family members of critically ill patients want to discuss loved ones' uncertain prognoses 2Health News:T'is the season to be jolly? 2Health News:Land Rover America's Polo Cup Team Plays in USPA World Snow Polo Championships, Aspen, Colorado 2Health News:Land Rover America's Polo Cup Team Plays in USPA World Snow Polo Championships, Aspen, Colorado 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: